AxoGen (AXGN) Corporate presentation summary

Market opportunity and unmet need

• US nerve-care opportunity totals $5.6B, with more than 1.5M peripheral nerve injuries annually requiring treatment in focus markets.

• Market estimates: extremities $2.9B, oral/maxillofacial and head & neck $1.2B, prostate surgery $754M, and breast reconstruction $677M.

• Nerve injuries can result from trauma, surgery, or amputation; stump pain associated with nerve damage has been reported in over 68% of amputees.

Products and strategic priorities

• Avance is described as the first approved biologic treatment for nerve discontinuities in adult and pediatric patients aged one month and older; it provides structural and biochemical cues for axonal regeneration.

• The nerve repair portfolio spans connection, protection, and termination, including Avance, Nerve Tape, Axoguard products, and Avive+ Soft Tissue Matrix.

• The 2025–2028 plan targets 15–20% CAGR, commercial expansion, elective and planned procedures, prostate market development, clinical evidence, and product innovation.

• Market development priorities address lagging care guidelines, low awareness, inefficient referrals, and coverage gaps; approximately 60% of nerve injuries go undiagnosed before discharge, while 4% of commercial lives remain uncovered.

• Clinical evidence programs include Avance studies in digital, mixed, motor, breast, and prostate nerve repair, plus studies of Axoguard nerve protection and nerve-end management.

Commercial reach and reimbursement

• Reach includes 6,500+ surgeons, more than 2,700 hospitals and outpatient centers, 275,000+ patients treated, and 350+ clinical and scientific publications.

• 2025 education activity included training 75% of hand fellows, 1,400 surgeons on the nerve repair algorithm, and more than 225 surgeons through 13 professional education programs.

• Avance coverage reached 93% of Medicare and Medicaid lives and 96% of commercial lives; 87.6M lives were added across Cigna, Elevance, Aetna, and 12 BCBS regional plans since Q2 2025.

• Extremities positioning cites Level 1 clinical evidence and health-economic value versus autograft, support from major societies, and comparable procedural cost to autograft.